In the News | Friends of Cancer Research

You are here

In the News

February 27, 2019
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to... Read more
February 20, 2019
Today we are discussing cancer clinical trial participation with Joseph Unger, PhD, MS, a health services researcher and biostatistician who is part of the public health sciences division at the Fred... Read more
February 11, 2019
Executive Summary Emerging standards for regulatory use of RWE should resist the temptation to impose the standards and expectations of randomized clinical trials to a fundamentally different kind of... Read more
February 8, 2019
Washington DC - Friends of Cancer Research (Friends) joins the nation in mourning the loss of former Democratic Representative John Dingell of Michigan. "For decades, the country counted on the... Read more
February 8, 2019
A notable benefit of using wearable devices and other innovative technology to collect patient data in real-time is to encourage the design and implementation of clinical trials conducted at the... Read more
February 8, 2019
SOME CANCER PATIENTS hope to join clinical trials, both to gain access to new treatments and to help improve treatment for future patients. Yet clinical trial eligibility requirements often state... Read more
February 5, 2019
Cancer in adolescents and young adults Her untimely death has once again shone a light on a global subgroup of 1 million cancer patients, referred to as adolescents and young adults (AYA), who, as of... Read more
February 1, 2019
The Lung Cancer Master Protocol is undergoing a major expansion to include patients with all non-small cell lung cancers.   The trial previously tested treatments for people with advanced stage... Read more
February 1, 2019
Easing comorbid-condition exclusion criteria could significantly increase participation in clinical trials for cancer, researchers report.   "Some eligibility exclusions for comorbid conditions will... Read more
February 1, 2019
FDA is enhancing its ability to handle real-world evidence by training reviewers in data science via a curriculum on machine learning and artificial intelligence, said FDA Commissioner Scott Gottlieb... Read more

Pages